Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat oral absorption in healthy subjects
NCT06193304Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eliglustat in Gaucher disease (GD), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration at Day 1, Time to Maximum Plasma Concentration at Day 1 and 5 more. Started Aug 2014; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT06193304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193304.